Legance - Avvocati Associati assists foreign and domestic clients from across the sector, including hospitals, pharmaceutical and biotech companies. The firm maintains a strong expertise in the industry’s regulatory framework as well as matters involving corporate, IP, compliance, administrative and competition law. Giovanni Nardulli is the firm’s head of practice and focuses his work on M&A matters, especially involving cross-border transactions. Pietro Merlino joined the firm in November 2023 from Orrick, Herrington & Sutcliffe.
Testimonials
Collated independently by Legal 500 research team.
‘The team is outstanding and responds promptly and accurately to all requests.’
‘Quality of the work and availability.’
Key clients
- Agilent Technologies
- Allergy Therapeutics
- Amplifon
- Castello SGR S.p.A.
- C.O.T. Cure Ortopediche Traumatologiche S.p.A.
- Diamante S.r.l.
- DWS
- Entangled Capital SGR
- Eusphera
- LIRH Foundation
- GB Pharma
- GKSD Parking S.r.l
- Gruppo San Donato
- Gruppo San Donato East Europe
- Gruppo Villa Maria
- GSD Healthcare
- Haemonetics
- Hippocrates Holding
- IRCCS Ospedale San Raffaele
- IRCCS Policlinico San Donato
- Kolinpharma S.p.A
- KOS Group
- Medipass S.p.A.
- MSD Italia
- Ospedale Galeazzi S.p.A.
- PRP
- RiverForce Partners
- Teva Italia
- UnipolSai
- U.G.A. Nutraceuticals
- Università Vita-Salute San Raffaele
Work highlights
- Assisted UnipolSai in the acquisition, from the L-GAM investment fund, of the entire share capital of Società e Salute, a company operating in the private healthcare sector under the brand name Centro Medico Santagostino.
- Assisted Ospedale San Raffaele (Scientific Institutes of Hospitalisation and Care (IRCCS)) and Università Vita-Salute San Raffaele for a partnership for the implementation and development of a neurotechnology laboratory, the Europe's largest of Walk Again Project.
- Assisted PRP in entering into an investment agreement and a shareholders’ agreement with Speira Quattro (a company ultimately controlled by Hyle Capital Partners SGR), in order to promote a voluntary tender offer for the entirety of Kolinpharma’s shares – through a special purpose vehicle in which PRP will reinvest its majority shareholding following the completion of the offer – aimed at delisting the company.
Practice head
The lawyer(s) leading their teams.
Giovanni Nardulli